What is William Blair’s Estimate for XENE Q1 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Monday, March 17th. William Blair analyst M. Minter anticipates that the biopharmaceutical company will post earnings per share of ($1.01) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($4.21) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05.

Several other research analysts have also issued reports on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $57.38.

Xenon Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:XENE opened at $34.85 on Wednesday. The firm has a market cap of $2.67 billion, a P/E ratio of -12.36 and a beta of 1.26. Xenon Pharmaceuticals has a 12-month low of $33.27 and a 12-month high of $46.00. The business has a fifty day simple moving average of $38.20 and a 200 day simple moving average of $39.92.

Insider Activity

In other news, CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,267,731. This trade represents a 34.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 5.52% of the stock is currently owned by company insiders.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $63,000. Quarry LP acquired a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $78,000. Blue Trust Inc. boosted its stake in Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 1,414 shares during the last quarter. Avior Wealth Management LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $101,000. Finally, KBC Group NV boosted its stake in Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 780 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.